Skip to content
Screener

BioMarin Pharmaceuticals BMRN EV / EBITDA

EV / EBITDA at other companies

PTC Therapeutics logo
PTC TherapeuticsPTCT
86.6×+82.7×
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
7.9×—
XER
Xeris Biopharma Holdings, Inc.XERS
40.5×—
Opko Health logo
Opko HealthOPK
28.5×—
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
38.3×-4.5×

Other financials

Income statement

See full
Revenue$989.7M+19.9%
Gross profit$786.9M+16.5%
Operating income$110.9M-59.9%
Net income$44.8M-81.4%
EPS (diluted)$0.23-81.3%

Balance sheet

See full
Cash & equivalents$874.0M-28.0%
Total debt$4.2B+598%
Total equity$6.3B+4.9%
Total assets$11.7B+57.2%

Cash flow

See full
Operating cash flow$168.1M-9.3%
CapEx$28.8M+68.5%
Free cash flow$139.3M-17.2%

Valuation

See full
Market cap$11.58B-0.6%
Enterprise value$14.89B+34.9%
P/E32.2×-34.7×
P/S3.4×-0.4×

Profitability

See full
Gross margin76.1%-3.4pp
Operating margin19.9%+7.2pp
Net margin16.8%+5.1pp
FCF margin21.7%-1.0pp

Returns & leverage

See full
Return on equity9.1%+2.8pp
Debt / equity0.7×+0.6×
Current ratio2.4×-3.2×

Where this comes from

Calculated from BioMarin Pharmaceuticals’s reported figures.

enterprise value/ebitda=41.1×

Based on the most recent quarter.

The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026. Open the filing →

Filed
Aug 6, 2026, 4:14 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001048477-26-000016

FAQ

What is BioMarin Pharmaceuticals's EV / EBITDA?
BioMarin Pharmaceuticals (BMRN) reported EV / EBITDA of 41.1× in Q2 2026.
How has BioMarin Pharmaceuticals's EV / EBITDA changed year-over-year?
BioMarin Pharmaceuticals's EV / EBITDA increased by 257.7% year-over-year, from 11.5× to 41.1×.
What is the long-term trend for BioMarin Pharmaceuticals's EV / EBITDA?
Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's EV / EBITDA has grown at a -39.7% compound annual growth rate (CAGR), from 251.2× to 20×.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.

Ask your AI about BioMarin Pharmaceuticals's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude